ClinicalTrials.gg
RecruitingNCT06818851HOLIDYAUpdated Jul 20, 2025

The Effects of Henagliflozin on Glucose Fluctuation and Immunosenescence in Type 2 Diabetes Patients on Insulin Therapy

A Phase 4 interventional study of Henggliflozin and Placebo in Diabetes Mellitus, Type 2, sponsored by Xinhua Hospital, Shanghai Jiao Tong University School of Medicine. Recruiting at 1 site in China. Open to participants aged 50 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-07-20.

Sponsored by Xinhua Hospital, Shanghai Jiao Tong University School of Medicine · Phase 4, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
50 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies testing henagliflozin in Diabetes Mellitus, Type 2 — 5 open to participants now, 5 under way, none of them phase 3. henagliflozin · Diabetes Mellitus, Type 2.

Planned enrollment
10th of 19
64 · median 64
Started
2025
the only one that year
Phase 4
5 of 19
4 open now
Registered
19th of 19
by date
Lead sponsor
1 of 19
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

Among the 19 studies testing henagliflozin in Diabetes Mellitus, Type 2, this one is the 10th largest by planned enrollment, is the only one that started in 2025, is one of 5 in phase 4, and was the 19th registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

5 of the 19 studies testing henagliflozin in Diabetes Mellitus, Type 2 are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

About henagliflozin

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 50 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing henagliflozin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if SGLT2 inhibitor Henggliflozin works to improve glucose variability in type 2 diabetes and if Henggliflozin can benefit immunosenescence.

The main questions it aims to answer are:

Does Henggliflozin as an add on treatment works to improve blood glucose fluctuation in type 2 diabetes? Does Henggliflozin has extra benefits like improve immunosenescence beyond hypoglycemic effects? Researchers will compare Henggliflozin to a placebo to see if Henggliflozin can improve glucose variability and immunosenescence.

Participants will:

Take Henggliflozin or a placebo every day for 16 weeks. Receive weekly follow-up calls to guide them in adjusting their insulin doses. Return for an on-site visit at 4 weeks and 16 weeks. Take a continuous glucose monitoring (CGM) for 7 days at the Visit 1 and at the end of the study.

Read the detailed description

With the rising prevalence of diabetes, complications associated with the disease are becoming a significant threat to human health. The primary goal of diabetes treatment is to delay the onset of macrovascular and microvascular complications and to reduce cardiovascular disease (CVD)-related mortality. Numerous clinical studies have explored the relationship between glycemic variability (GV) and the risk of macrovascular disease. Recent research has shown that GV is closely associated with endothelial cell damage, which represents an early stage of atherosclerosis and serves as a predictive factor for CVD.

The mean amplitude of glycemic excursions (MAGE), a marker of daily GV related to postprandial hyperglycemia or hypoglycemia, is a critical determinant of the severity of coronary artery disease and an independent predictor of mortality risk. Over the long term, reducing daily GV can help lower cardiovascular events and mitigate cognitive decline in patients. Therefore, controlling GV is particularly important in reducing the risk of cardiovascular disease.

While there is no strong evidence yet to suggest that suppressing GV can directly reverse cardiovascular events, some studies indicate that antidiabetic medications that reduce GV can improve surrogate markers of cardiovascular risk factors. Sodium-glucose cotransporter 2 (SGLT2) inhibitors lower blood glucose by promoting glucose excretion through urine. Research has demonstrated that SGLT2 inhibitors can reduce cardiovascular risks; however, studies on their effect in suppressing GV remain insufficient.

This study is a multicenter, randomized, double-blind controlled trial aiming to enroll 64 participants with type 2 diabetes.

Eligible participants will be randomly assigned to one of two groups in a 1:1 ratio:

  • Henggliflozin Group (n=32): Henggliflozin 10 mg, once daily.
  • Placebo Control Group (n=32): Placebo, once daily.

Upon enrollment, at Visit 1 (baseline), overnight fasting blood and urine samples will be collected, and glucose levels will be monitored for 3-5 days using a continuous glucose monitoring (CGM) system. After the preliminary assessment, participants will receive either Henggliflozin 10 mg or a placebo once daily by oral administration for up to 16 weeks.

During the treatment period, weekly follow-up calls will be conducted to guide participants in adjusting their insulin doses until fasting blood glucose (FBG) reaches the target level (\<7 mmol/L). Participants will return for an on-site visit at 4 weeks, during which medications will be retrieved, and relevant information recorded. Other antidiabetic medications, such as metformin, sulfonylureas, glinides, thiazolidinediones, or α-glucosidase inhibitors, may continue to be used at unchanged doses throughout the study. Participants will be encouraged to maintain their dietary and exercise regimens. If there is a risk of hypoglycemia, insulin doses may be reduced.

At the end of the 16-week treatment period, medications will be retrieved again, and fasting blood and urine samples will be collected. Glucose monitoring will be repeated using the CGM system. A safety follow-up call will be conducted two weeks after the end of the study.

03

Conditions studied

  • Diabetes Mellitus, Type 2

Keywords

  • Sodium-glucose cotransporter 2
  • glycemic variability
  • immunosenescence
04

Who can participate

Ages eligible
50 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed with type 2 diabetes mellitus (T2DM) for at least 6 months based on the 1999 WHO criteria.

    • Age between 50 and 70 years at the time of signing the form (inclusive).
    • Poor glycemic control despite treatment with basal insulin or insulin degludec/aspart (with or without oral antidiabetic drugs) within the 3 months prior to screening.
    • level above 8%.
    • ≥ 20 kg/m².
    • C-peptide levels within the normal reference range.
    • Able to maintain stable dietary and exercise habits during the study.
    • Capable of understanding the study procedures and methods, willing to strictly comply with the clinical trial protocol, and voluntarily sign the informed consent form.

Exclusion criteria

Exclusion Criteria:

  • Patients considered by the investigator to have potential allergies to the components of the study drug or drugs of the same class.

    • Use of SGLT2 inhibitors or GLP-1 receptor agonists within 3 months prior to screening.
    • Adjustments to antidiabetic treatment regimens within 3 months prior to screening.
    • Hospitalization due to acute coronary syndrome (ST-segment elevation myocardial infarction, non-ST-segment elevation myocardial infarction, or unstable angina), percutaneous coronary intervention, or cardiac surgery within 30 days prior to the screening visit.
    • Volume depletion.
    • Chronic (>2 weeks) systemic therapy or use of glucocorticoids within 4 weeks prior to screening (except for topical, intraocular, intranasal, or inhaled administration).
    • Pregnancy, lactation, or plans for pregnancy within the next 6 months.
    • Persistently elevated serum transaminase levels (more than 3 times the ).
    • Renal impairment (estimated [eGFR] \< 45 mL/min/1.73 m²).
    • History of malignant tumors.
    • Presence of acute complications (e.g., ketoacidosis, diabetic ketoacidosis, lactic acidosis, or hyperosmolar coma).
    • Systemic diseases, such as systemic lupus erythematosus.
    • urinary tract infections and/or genital infections, or a history of recurrent urinary tract and/or genital infections.
    • Any other factors deemed by the investigator to potentially affect the efficacy or safety evaluation of the study.
    • Participation in other clinical trials and receipt of drugs within 3 months prior to screening.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
64 participants (estimated)

Study arms

  • Experimental
    Experimental Group

    Henggliflozin 10mg per day for 16 weeks

    Drug: Henggliflozin

  • Placebo comparator
    Control Group

    Placebo 10mg per day for 16 weeks

    Other: Placebo

Interventions

  • DrugHenagliflozinStudies of HenagliflozinHenagliflozin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Upon enrollment, at Visit 1 (baseline), overnight fasting blood and urine samples will be collected, and glucose levels will be monitored for 3-5 days using a continuous glucose monitoring (CGM) system (Medtronic MiniMed). After the preliminary assessment, participants will receiveHenggliflozin 10 mg once daily by oral administration for up to 16 weeks.

  • OtherPlacebo

    Upon enrollment, at Visit 1 (baseline), overnight fasting blood and urine samples will be collected, and glucose levels will be monitored for 3-5 days using a continuous glucose monitoring (CGM) system (Medtronic MiniMed). After the preliminary assessment, participants will receive a placebo once daily by oral administration for up to 16 weeks.

06

What researchers measure

Primary outcomes

  1. Change from Baseline in the mean amplitude of glycemic excursions at 16 weeks

    Time frame: From enrollment to the end of treatment at 16 weeks

Secondary outcomes

  1. Change from Baseline in the immunophenotype of peripheral blood mononuclear cells at 16 weeks

    Time frame: From enrollment to the end of treatment at 16 weeks

07

Study locations

1 of 1 sites recruiting
  • Shanghai Jiaotong University School of Medicine, Xinhua Hospital
    Shanghai, Shanghai Municipality 200092, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Dec 2027, 29 months after the start.

Of 320 non-industry phase 4 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 49. This study's planned 29 months is close to that.

Counting every sponsor, half of 452 studies reached it within 24 months; a quarter within 13 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 23, 2025
First posted
Feb 11, 2025
StartActual
Jul 14, 2025
Primary completionEst.
Dec 31, 2027
CompletionEst.
Mar 30, 2028
Last update
Jul 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06818851
Responsible party
Sponsor
First posted
Feb 11, 2025
Start date
Jul 14, 2025
Primary completion
Dec 31, 2027 (estimated)
Completion
Mar 30, 2028 (estimated)
Last update
Jul 20, 2025

Study contacts

Hongmei Zhang
Contact
spicygirlss@126.com
+8613636347760
Qing Su
study director · Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Henagliflozin

Start the discussion